BEL­LUS Health buys IP rights, ban­ish­es roy­al­ties; Ab­b­Vie gets con­fir­ma­to­ry da­ta on ac­cel­er­at­ed AML drug

→ Cana­da’s BEL­LUS Health $BLU has bagged the re­main­ing IP rights for its BLU-5937 and re­lat­ed P2X3 an­tag­o­nists. The deal scraps the tiered roy­al­ty pay­ments that would have been due to ad­Mare BioIn­no­va­tions’ NEOMED In­sti­tute. As­traZeneca as­signed that to them in 2012. BEL­LUS Health ex­changed 7.3% of its eq­ui­ty for the rights.

→ Schrödinger $SD­GR has ex­pand­ed its com­pu­ta­tion­al re­search col­lab­o­ra­tion with As­traZeneca. Al­ready work­ing on small mol­e­cule drug dis­cov­ery, they’ll now al­so be “fo­cused on re­fin­ing a bi­o­log­ics mod­el­ing so­lu­tion with the aim of speed­ing up the de­vel­op­ment of an­ti­body and pro­tein-based ther­a­peu­tic can­di­dates.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER